Sustained appearance of drug resistance-associated mutations in HIV-1 CRF01-AE protease and reverse transcriptase derived from protease inhibitor-naive Thai patients

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 41, Issue 2, 2010, Pages 347-357

  Jullaksorn, Duangrat ^a   Boonchawalit, Samatchaya ^b   Uttiyoung, Jiraporn ^b   Soonthornsata, Bongkot ^b   Yowang, Amara ^b   Krathong, Nongkran ^c   Chautrakul, Sununta ^c   Ikuta, Kazuyoshi ^b,d   Roobsoong, Amornsak ^c   Kanitvittaya, Sangkom ^b   Sawanpanyalert, Pathom ^a   Kameoka, Masanori ^b,d  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

^c Mae Suai Hospital   (Thailand)

^d OSAKA UNIVERSITY   (Japan)

Author keywords

Drug resistance associated mutations; HIV 1 CRF01 AE virus; Protease; Reserve transcriptase

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; RNA DIRECTED DNA POLYMERASE;

ANTIVIRAL RESISTANCE; CD4 LYMPHOCYTE COUNT; DNA SEQUENCE; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MOLECULAR GENETICS; MUTATION; POLYMERASE CHAIN REACTION; THAILAND; VIROLOGY; VIRUS LOAD;

CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; THAILAND; VIRAL LOAD;

EID: 77956015652     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Adachi A, Gendelman HE, Koenig S, et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986;59:284-91.
2. Auwanit W, Isarangkura-Na-Ayuthaya P, Kasornpikul D, Ikuta K, Sawanpanyalert P, Kameoka M. Detection of drug resistance-associated and background mutations in human immunodeficiency virus type 1 CRF01-AE protease and reverse transcriptase derived from drug treatment-naive patients residing in central Thailand. AIDS Res Hum Retroviruses 2009;25:625-31.
3. Birk M, Sonnerborg A. Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients. AIDS 1998;12:2369-75.
4. Bon I, Gibellini D, Borderi M, et al. Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients. J Clin Virol 2007;38:313-20.
5. Conway B, Wainberg MA, Hall D, et al. Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. AIDS 2001;15:1269-74.
6. DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000;5:41-8.
7. Gulick RM, Mellors JW, Havlir D, et al. Tr eatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
8. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337:725-33.
9. Handema R, Terunuma H, Kasolo F, et al. Prevalence of drug-resistance-associated mutations in antiretroviral drug-naive Zambians infected with subtype C HIV-1. AIDS Res Hum Retroviruses 2003;19:151-60.
10. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006;20:W13-23.
11. Holguin A, Paxinos E, Hertogs K, Womac C, Soriano V. Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. J Clin Virol 2004;31:215-20.
12. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008;16:138-45.
13. Lech WJ, Wang G, Yang YL, et al. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects. J Virol 1996;70:2038-43.
14. McCutchan FE. Global epidemiology of HIV. J Med Virol 2006;78(suppl 1):S7-12.
15. Nukoolkarn S, Pongthapisith V, Panyim S, Leelamanit W. Sequence variability of the HIV type 1 protease gene in thai patients experienced with antiretroviral therapy. AIDS Res Hum Retroviruses 2004;20:1368-72.
16. Pieniazek D, Rayfield M, Hu DJ, et al. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group. AIDS 2000;14:1489-95.
17. Ross L, Johnson M, DeMasi R, et al. Viral genetic heterogeneity in HIV-1-infected individuals is associated with increasing use of HAART and higher viremia. AIDS 2000;14:813-9.
18. Shafer RW, Schapiro JM. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev 2008;10:67-84.
19. Sukasem C, Churdboonchart V, Sirisidthi K, et al. Genotypic resistance mutations in treatment-naive and treatment-experienced patients under widespread use of antiretroviral drugs in Thailand: implications for further epidemiologic surveillance. Jpn J Infect Dis 2007;60:284-9.
20. Sukasem C, Churdboonchart V, Sukeepaisarncharoen W, et al. Genotypic resistance profiles in antiretroviral-naive HIV-1 infections before and after initiation of first-line HAART: impact of polymorphism on resistance to therapy. Int J Antimicrob Agents 2008;31:277-81.
21. Sutthent R, Arworn D, Kaoriangudom S, et al. HIV-1 drug resistance in Thailand: before and after National Access to Antiretroviral Program. J Clin Virol 2005;34:272-6.
22. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, positionspecific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22:4673-80.
23. Vergne L, Peeters M, Mpoudi-Ngole E, et al. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 2000;38:3919-25.
24. Vergne L, Stuyver L, Van Houtte M, Butel C, Delaporte E, Peeters M. Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients. J Clin Virol 2006;36:43-9.